On August 5, 2024, Suzhou Broadcasting System's journalists visited RocRock Bio in BioBAY, Suzhou Industrial Park, and had an in-depth interview with Dr. Xiushan Yin , the founder. They also toured the company's laboratory. The interview was highlighted in the Suzhou News, reflecting RocRock Bio's research capabilities, innovation, and successful international collaborations.
https://www.bilibili.com/video/BV1jn9uYfEbe/spm_id_from=333.1387.search.video_card.click&vd_source=03c176f8c4a5774ff50af127a875a5f1
During the pandemic's early stages, RocRock Bio's core team forged a strong partnership with Armenia, aiding in establishing a testing kit production and technology platform. From July 7 to 10, 2024, Dr. Xiushan Yin led a delegation from RocRock Bio and Shandong First Medical University to visit Armenia, a country along the Belt and Road. The visit focused on Mediterranean fever prevention and treatment, leading to a cooperation intention for a China-Armenia national rare disease project.
Ashot Saghyan, president of Armenia's top scientific research institution, the National Academy of Sciences, presented a national gold medal to Dr. Yin Xiushan. This award honors Xiushan Yin's substantial contributions to Armenia's healthcare during the COVID-19 pandemic.
Drawing on its successful test-kit development and accumulated expertise, RocRock Bio has partnered with Shandong First Medical University to set up joint laboratories in Armenia and China. This collaboration has achieved significant progress in developing drugs for Familial Mediterranean Fever (FMF), with plans to launch clinical trials in the second half of this year. This partnership represents a trailblazing global effort to enhance the accessibility of rare disease treatment technologies, rather than focusing solely on drug development. It aims to tackle the issue of high medical costs for rare diseases and make treatments more accessible to patients.
RocRock Bio is dedicated to developing macrophage - based therapeutics for solid tumors. The company has made significant progress in CAR-M R&D and is working on multiple drug pipelines for various cancers and diseases. With a goal to launch two innovative drugs in 5 - 6 years, RocRock Bio aims to position China as a leader in macrophage - based solid tumor treatment. The company follows the "Belt and Road" initiative, collaborates with global institutes, and continuously expands its product pipeline to bring more therapies to patients.
No Code Website Builder